% | $
Quotes you view appear here for quick access.

Vertex Pharmaceuticals Incorporated Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • swhitemd50 swhitemd50 Dec 7, 2011 2:02 PM Flag

    If you are right

    I think the Pharmasset strategy is to get the FDA to approve their PSI-7977/RBV oral regimen for interferon intolerant HCV patients, regardless of genotype, and then market the combo to every HCV patient even if it has a low cure rate for GT1. Using the vague designation "interferon intolerant," you can include any patient that might not want to experience influenza-like side effects. And wouldn't that include everyone?

81.90-6.30(-7.14%)Jun 24 4:00 PMEDT